Petkovich · Cell metabolism 2017 · Preclinical biomarker development and validation study · n=?

Using DNA Methylation Profiling to Evaluate Biological Age and Longevity Interventions.

Cited 450 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal and in vitro biomarker development study without human clinical data.

PubMed 28380383 · doi:10.1016/j.cmet.2017.03.016 · record verified 2026-08-30

What was done

Researchers developed an epigenetic predictor of mouse biological age using partial blood DNA methylation profiles across 90 CpG sites. The clock was evaluated for its ability to determine chronological age in mouse cohorts, detect the effects of longevity interventions (calorie restriction and gene knockouts), and assess cellular rejuvenation in fibroblast-derived induced pluripotent stem cells (iPSCs).

What was found

The 90-CpG clock tracked age in mouse cohorts, identified the longevity-extending effects of calorie restriction and gene knockouts, and detected rejuvenation in iPSCs. The authors observed that the relevant CpG sites are scattered across the genome, show gradual methylation changes over time, and differ between mice and humans. The abstract reports no numerical values, correlation statistics, or error rates.

Why it matters

This provides a validated epigenetic biomarker of aging in mice that responds to established life-extending interventions. It enables researchers to evaluate potential anti-aging interventions in preclinical animal models without waiting for full lifespan outcomes.

Limits

The abstract reports no sample sizes for animal cohorts or cell lines, nor does it provide quantitative performance metrics such as mean absolute error or correlation coefficients. The clock is developed in mice, and the authors note that the specific age-associated CpG sites are distinct from those in humans.

Cited by